Literature DB >> 33704556

Cognitive and behavioral profile of progressive supranuclear palsy and its phenotypes.

Andrea Horta-Barba1,2,3,4,5, Javier Pagonabarraga6,7,8,9, Saül Martínez-Horta1,2,3,4, Laura Busteed1, Berta Pascual-Sedano1,2,3,4,5, Ignacio Illán-Gala3,4,10, Juan Marin-Lahoz1,2,3, Ignacio Aracil-Bolaños1,2,3,4, Jesús Pérez-Pérez1,2,3,4, Frederic Sampedro1,3,4, Helena Bejr-Kasem1,2,3,4,5, Jaime Kulisevsky11,12,13,14,15.   

Abstract

BACKGROUND: Although several progressive supranuclear palsy (PSP) phenotypes have recently been described, studies identifying cognitive and neuropsychiatric differences between them are lacking.
METHODS: An extensive battery of cognitive and behavioural assessments was administered to 63 PSP patients, 25 PD patients with similar sociodemographic characteristics, and 25 healthy controls. We analysed differences in phenomenology, frequency and severity of cognitive and neuropsychiatric symptoms between PSP, PD and HC, and between PSP subtypes.
RESULTS: Regarding phenotypes, 64.6% met criteria for Richardson's syndrome (PSP-RS), 10.7% PSP with predominant Parkinsonism (PSP-P), 10.7% with PSP progressive gait freezing (PSP-PGF), and 10.7% PSP with predominant speech/language disorder (PSP-SL). Impairment was more severe in the PSP group than in the PD and HC groups regarding motor scores, cognitive testing and neuropsychiatric scales. Cognitive testing did not clearly differentiate between PSP phenotypes, but PSP-RS and PSP-SL appeared to have more cognitive impairment than PSP-PGF and PSP-P, mainly due to an increased impairment in frontal executive domains. Regarding neuropsychiatric disturbances, no specific behavior was more common in any of the PSP subtypes.
CONCLUSION: Motor deficits delineate the phenotypes included in currently accepted MDS-PSP criteria. Cognition and behavioural disturbances are common in PSP and allow us to distinguish this disorder from other neurological diseases, but they do not differentiate between PSP phenotypes.

Entities:  

Keywords:  Behavior; Cognition; Motor features; PSP phenotypes; Progressive supranuclear palsy

Year:  2021        PMID: 33704556     DOI: 10.1007/s00415-021-10511-y

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  31 in total

1.  Accuracy of clinical diagnosis of progressive supranuclear palsy.

Authors:  Yasushi Osaki; Yoav Ben-Shlomo; Andrew J Lees; Susan E Daniel; Carlo Colosimo; Gregor Wenning; Niall Quinn
Journal:  Mov Disord       Date:  2004-02       Impact factor: 10.338

2.  Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy.

Authors:  Farwa Ali; Peter R Martin; Hugo Botha; J Eric Ahlskog; James H Bower; Joseph Y Masumoto; Demetrius Maraganore; Anhar Hassan; Scott Eggers; Bradley F Boeve; David S Knopman; Daniel Drubach; Ronald C Petersen; Erika Driver Dunkley; Jay van Gerpen; Ryan Uitti; Jennifer L Whitwell; Dennis W Dickson; Keith A Josephs
Journal:  Mov Disord       Date:  2019-02-06       Impact factor: 10.338

Review 3.  Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.

Authors:  Adam L Boxer; Jin-Tai Yu; Lawrence I Golbe; Irene Litvan; Anthony E Lang; Günter U Höglinger
Journal:  Lancet Neurol       Date:  2017-06-13       Impact factor: 44.182

4.  The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK.

Authors:  U Nath; Y Ben-Shlomo; R G Thomson; H R Morris; N W Wood; A J Lees; D J Burn
Journal:  Brain       Date:  2001-07       Impact factor: 13.501

5.  Comparison of motor, cognitive, and behavioral features in progressive supranuclear palsy and Parkinson's disease.

Authors:  Nicholas J Cordato; Glenda M Halliday; Diana Caine; John G L Morris
Journal:  Mov Disord       Date:  2006-05       Impact factor: 10.338

Review 6.  Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges.

Authors:  David R Williams; Andrew J Lees
Journal:  Lancet Neurol       Date:  2009-03       Impact factor: 44.182

7.  The Progressive Supranuclear Palsy: Past and Present Aspects.

Authors:  Theodore P Parthimos; Kleopatra H Schulpis
Journal:  Clin Gerontol       Date:  2019-11-22       Impact factor: 2.619

Review 8.  Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease.

Authors:  Angie A Kehagia; Roger A Barker; Trevor W Robbins
Journal:  Lancet Neurol       Date:  2010-09-27       Impact factor: 44.182

Review 9.  Cognition in corticobasal syndrome and progressive supranuclear palsy: a review.

Authors:  James R Burrell; John R Hodges; James B Rowe
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

10.  The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases.

Authors:  Gesine Respondek; Maria Stamelou; Carolin Kurz; Leslie W Ferguson; Alexander Rajput; Wan Zheng Chiu; John C van Swieten; Claire Troakes; Safa Al Sarraj; Ellen Gelpi; Carles Gaig; Eduardo Tolosa; Wolfgang H Oertel; Armin Giese; Sigrun Roeber; Thomas Arzberger; Stefan Wagenpfeil; Günter U Höglinger
Journal:  Mov Disord       Date:  2014-11-05       Impact factor: 10.338

View more
  6 in total

Review 1.  Social cognition in the FTLD spectrum: evidence from MRI.

Authors:  Maria Antonietta Magno; Elisa Canu; Massimo Filippi; Federica Agosta
Journal:  J Neurol       Date:  2021-11-19       Impact factor: 4.849

Review 2.  The Cognitive Profile of Atypical Parkinsonism: A Meta-Analysis.

Authors:  Simona Raimo; Mariachiara Gaita; Maria Cropano; Giusi Mautone; Alfonsina D'Iorio; Luigi Trojano; Gabriella Santangelo
Journal:  Neuropsychol Rev       Date:  2022-08-12       Impact factor: 6.940

3.  The Burden of Progressive Supranuclear Palsy on Patients, Caregivers, and Healthcare Systems by PSP Phenotype: A Cross-Sectional Study.

Authors:  Demetris Pillas; Alexander Klein; Teresa Gasalla; Andreja Avbersek; Alexander Thompson; Jack Wright; Jennifer Mellor; Anna Scowcroft
Journal:  Front Neurol       Date:  2022-07-04       Impact factor: 4.086

Review 4.  Clinical Spectrum of Tauopathies.

Authors:  Nahid Olfati; Ali Shoeibi; Irene Litvan
Journal:  Front Neurol       Date:  2022-07-14       Impact factor: 4.086

5.  Striatal dopaminergic lesions contributed to the disease severity in progressive supranuclear palsy.

Authors:  Ming-Jia Chen; Jia-Ying Lu; Xin-Yi Li; Fang-Yang Jiao; Chuan-Tao Zuo; Jian Wang; Feng-Tao Liu; Yu-Jie Yang
Journal:  Front Aging Neurosci       Date:  2022-08-24       Impact factor: 5.702

6.  Diagnostic Performance of the Magnetic Resonance Parkinsonism Index in Differentiating Progressive Supranuclear Palsy from Parkinson's Disease: An Updated Systematic Review and Meta-Analysis.

Authors:  Seongken Kim; Chong Hyun Suh; Woo Hyun Shim; Sang Joon Kim
Journal:  Diagnostics (Basel)       Date:  2021-12-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.